PONATINIB

ponatinib 15 mg tablet, 60

PONATINIB (10523W)

ponatinib 15 mg tablet, 60
10523W
Body System:
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Acute lymphoblastic leukaemia
Treatment phase: Initial treatment

Restriction

Indication: Acute lymphoblastic leukaemia
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 2 DPMQ: $5,224.70 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Iclusig